Browse studies

Find your next paid study

3,219 recruiting studies matching your filters

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells gene…

Pediatric Solid TumorOsteosarcomaRhabdomyosarcoma+13 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT04897321

Phase 2

Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum wom…

Post-Dural Puncture Headache

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT05116930

Phase 1

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas…

Diffuse Midline Glioma (DMG)GlioblastomaRecurrent Ependymoma+5 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Sabine Mueller, MD, PhDNCT04732065

Phase 1

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

This Phase I, single-institution, open-label study will evaluate the safety, tolerability, and diagnostic performance of \[18F\]NOTA-ABY030 PET/CT in patients …

SCC - Squamous Cell CarcinomaRadiotracerHead and Neck Squamous Cell Carcinoma+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Vanderbilt-Ingram Cancer CenterNCT07217028

Phase 3

Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism

This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy,…

Hypogonadism, Male

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Halozyme TherapeuticsNCT06689085

Proton Therapy Patient Registry

The purpose of this study is to establish a database (or "registry") of patients treated with proton beam therapy at the University Hospitals (UH) Proton Thera…

Treatment With Proton Beam Radiation Therapy

Estimated

~$10 – $750

Actual pay is set by the research site.

Case Comprehensive Cancer CenterNCT02986048

Phase 2

GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence - A Pilot Study

This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (C…

WHO Grade 3 GliomaWHO Grade 4 Glioma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT06444412

Phase 1

A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies

This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in …

Ovarian CancerAdvanced Malignant Solid Tumor

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of ChicagoNCT07389239

Phase 1

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safet…

Advanced or Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Hanmi Pharmaceutical Company LimitedNCT06724016

Advancing Identification of Circadian Delay in ADHD Youth: Associations With Clinical Heterogeneity and Cognition

The purpose of this study is to better understand sleep and circadian functioning in children with ADHD using home-based measures, parent report, and a lab bas…

ADHD - Attention Deficit Disorder With HyperactivityADHD

Estimated

~$10 – $750

Actual pay is set by the research site.

Duke UniversityNCT06971640

Phase 1

Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Triple Negative Breast Cancer (TNBC)

This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+24 more

Estimated

Phase 2

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a geno…

Lymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors

Estimated

~$75 – $2,000

Actual pay is set by the research site.

American Society of Clinical OncologyNCT02693535